These findings offer a possibility that BET inhibitors are combined with anti-PD-L1 therapeutics or PARP inhibitors for cancer therapy, thus greatly expanding the potential therapeutic scope of BET inhibitors7,9. This evidence concerns the gene DNER and cancer.